E
WST icon

Ergoteles’s West Pharmaceutical WST Stock Holding History

Ergoteles’s Portfolio WST Stock Details WST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-4,030
Closed -$948K – 1801
2022
Q4 		$948K Sell
4,030
-3,039
-43% -$720K 0.03% 475
2022
Q3 		$1.74M Buy
7,069
+4,723
+201% +$1.44M 0.06% 316
2022
Q2 		$709K Sell
2,346
-3,323
-59% -$1.08M 0.02% 686
2022
Q1 		$2.33M Buy
5,669
+4,548
+406% +$1.78M 0.09% 230
2021
Q4 		$526K Buy
+1,121
New +$483K 0.02% 620
2021
Q3 		– Sell
-2,177
Closed -$782K – 1728
2021
Q2 		$782K Sell
2,177
-9,723
-82% -$3.21M 0.02% 598
2021
Q1 		$3.35M Sell
11,900
-61,700
-84% -$17.7M 0.1% 218
2020
Q4 		$20.9M Buy
+73,600
New +$20.7M 0.69% 36

Other funds holding WST

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
APG Asset Management
APG Asset Management Amsterdam, Netherlands $40.7B AUM 39.97% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Ergoteles's WST Position: Q1 2023 in Review

Ergoteles sold out of West Pharmaceutical (WST) in Q1 2023, closing a stake of 4,030 shares — an estimated $948K sold.

Ergoteles first reported a position in WST in Q4 2020 and held it in 8 quarters. The position peaked at $20.9M in Q4 2020. 695 funds tracked by Wall St. Rank hold WST as of Q1 2023.

  • Ergoteles reported no remaining West Pharmaceutical position as of Q1 2023 after selling out during the quarter.
  • Ergoteles sold 4,030 West Pharmaceutical shares in Q1 2023, an estimated $948K.
  • Ergoteles first reported a position in West Pharmaceutical in Q4 2020 and held it in 8 quarters.
  • Ergoteles's West Pharmaceutical position peaked at $20.9M in Q4 2020.
  • 695 funds tracked by Wall St. Rank held West Pharmaceutical as of Q1 2023.

Based on Ergoteles's 13F filing for Q1 2023, filed 10 May 2023.